Maze Therapeutics Reports $20 Million License Revenue and $24.2 Million Net Loss in Q1 2026

Maze Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a license revenue of $20 million, a significant increase from zero revenue in the same period last year. This revenue was primarily attributed to a milestone payment from Shionogi & Co., Ltd. related to the clinical development of MZE001, a therapeutic candidate for Pompe disease. Despite this revenue, the company incurred a net loss of $24.2 million for the quarter, an improvement compared to the $32.8 million loss reported in the first quarter of 2025. The loss per share decreased to $0.45 from $1.15 year-over-year, reflecting a reduction in operational losses.

Operating expenses for the quarter totaled $46.6 million, up from $35.4 million in the prior year, driven by increased research and development costs, which rose to $34.1 million from $27.6 million. This increase was largely due to higher personnel-related costs and expenses associated with clinical trials for its lead programs, MZE829 and MZE782. General and administrative expenses also increased to $12.4 million, up from $7.8 million, reflecting the company's growth and the costs associated with being a public entity.

Maze Therapeutics has made strategic advancements, including entering into a Hercules Loan Agreement in February 2026, which provides for a senior secured term loan facility of up to $200 million. The initial loan of $40 million has been funded, with additional tranches available based on performance milestones. The company also initiated an at-the-market offering program with Jefferies LLC, allowing it to raise up to $200 million through the sale of common stock, although no sales have occurred under this agreement to date.

As of March 31, 2026, Maze Therapeutics reported cash, cash equivalents, and marketable securities totaling $362.9 million, which the company believes will be sufficient to fund operations for at least the next year. The company continues to focus on advancing its clinical programs and expanding its pipeline of therapeutic candidates. Looking ahead, Maze Therapeutics anticipates continued operational losses as it invests in research and development, with plans to initiate Phase 2 trials for MZE782 in patients with phenylketonuria and chronic kidney disease later in 2026. The company remains committed to leveraging its Compass platform to identify new therapeutic targets and advance its clinical development efforts.